投资研究公司Vanda Research数据显示，诺和诺德上周五单日净资金流入飙升32倍，从前一天的49万美元攀升至1560万美元，因为其令人失望的减肥药数据提供罕见的逢低进场机会。诺和诺德公布的数据表明，实验药物CagriSema只帮助患者减轻22.7%的体重，不及预期的25%。诺和诺德美股上周五盘中一度暴跌 21%，至81.5美元，为2023年8月以来的最低水平。
Vanda研究部门资深副总裁 Marco Iachini 表示：“散户喜欢逢低买入，尤其是热门股票...... 而且会这么做，直到这种做法不再奏效。目前诺和诺德的表现两年来首次低于标普500指数，因此要看到他们(散户投资人)放弃逢低买入的倾向可能还为时过早。”上周五的散户资金流动可能为机构投资人提供了退出管道。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.